Quantcast

Tarveda Therapeutics to Present at Needham & Company’s 18th Annual Healthcare Conference

WATERTOWN, Mass.–(BUSINESS WIRE)–Tarveda
Therapeutics, Inc.
, a clinical stage biopharmaceutical company
discovering and developing a new class of potent and selective miniature
drug conjugates (Pentarins®) for the treatment of patients
with a wide range of solid tumors, today announced that Drew Fromkin,
President and Chief Executive Officer, will present at Needham &
Company’s 18th Annual Healthcare Conference, occurring April
9-10, 2019 in New York City. Tarveda presentation details:

Date: Tuesday, April 9, 2019
Time: 1:10pm Eastern Time
Location:
Westin Grand Central, New York, NY

About Tarveda Therapeutics, Inc.

Tarveda Therapeutics, Inc. is discovering and developing a new class of
potent and selective miniature drug conjugates (Pentarins®)
for the treatment of patients with a wide range of solid tumors. PEN-221
is a miniature drug conjugate in clinical evaluation for the treatment
of patients with somatostatin receptor 2 (SSTR2) expressing
neuroendocrine, small cell lung and other solid tumors. PEN-221 is
highly selective for SSTR2 and is designed to rapidly penetrate deep
into solid tumors where it accumulates and releases its potent DM1
payload over time within the tumor cells. Tarveda is also advancing its
HSP90 binding drug conjugate platform with lead drug candidate PEN-866,
which selectively binds in tumors to the activated form of Heat Shock
Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor
payload, SN38. The safety and efficacy of PEN-866 in patients with
cancer is currently being evaluated in a clinical trial. Tarveda’s
strategy includes developing its own proprietary miniature drug
conjugates as well as applying its miniature drug conjugate platform to
enhance the effectiveness of the targeting moieties and novel payloads
of pharmaceutical collaborators. www.tarvedatx.com

Contacts

Amanda Houlihan
MacDougall
781 235 3060
[email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.